Free Trial

Neumora Therapeutics (NMRA) Competitors

Neumora Therapeutics logo
$1.71 -0.09 (-5.00%)
Closing price 10/22/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.02 (+0.88%)
As of 10/22/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NMRA vs. TRVI, IMNM, WVE, CVAC, MAZE, ATAI, CALT, ARDX, SYRE, and PHVS

Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Trevi Therapeutics (TRVI), Immunome (IMNM), WAVE Life Sciences (WVE), CureVac (CVAC), Maze Therapeutics (MAZE), atai Life Sciences (ATAI), Calliditas Therapeutics AB (publ) (CALT), Ardelyx (ARDX), Spyre Therapeutics (SYRE), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

Neumora Therapeutics vs. Its Competitors

Neumora Therapeutics (NASDAQ:NMRA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neumora TherapeuticsN/AN/A-$243.79M-$1.57-1.09
Trevi TherapeuticsN/AN/A-$47.91M-$0.42-25.93

Neumora Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Trevi Therapeutics' return on equity of -41.44% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neumora TherapeuticsN/A -98.95% -87.68%
Trevi Therapeutics N/A -41.44%-38.21%

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Neumora Therapeutics' average media sentiment score of 0.00 equaled Trevi Therapeutics'average media sentiment score.

Company Overall Sentiment
Neumora Therapeutics Neutral
Trevi Therapeutics Neutral

Neumora Therapeutics currently has a consensus target price of $7.14, indicating a potential upside of 317.71%. Trevi Therapeutics has a consensus target price of $21.75, indicating a potential upside of 99.72%. Given Neumora Therapeutics' higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Trevi Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neumora Therapeutics
3 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00
Trevi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Summary

Trevi Therapeutics beats Neumora Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMRA vs. The Competition

MetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$291.50M$3.47B$6.17B$10.67B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-1.0922.9129.0927.13
Price / SalesN/A463.56584.28126.20
Price / CashN/A45.5937.1261.42
Price / Book0.9610.2912.246.43
Net Income-$243.79M-$52.53M$3.33B$276.63M
7 Day Performance-3.93%-0.60%-0.79%-0.77%
1 Month Performance-10.47%10.30%5.27%0.68%
1 Year Performance-87.15%13.51%69.02%32.03%

Neumora Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMRA
Neumora Therapeutics
1.9537 of 5 stars
$1.71
-5.0%
$7.14
+317.7%
-87.8%$291.50MN/A-1.09108
TRVI
Trevi Therapeutics
1.96 of 5 stars
$9.71
-2.8%
$21.75
+124.0%
+237.2%$1.22BN/A-23.1220
IMNM
Immunome
1.7766 of 5 stars
$14.25
+2.4%
$23.20
+62.8%
+35.8%$1.21B$9.04M-4.6340News Coverage
WVE
WAVE Life Sciences
4.6779 of 5 stars
$7.79
+2.5%
$20.33
+161.0%
-51.6%$1.21B$108.30M-8.66240Analyst Forecast
CVAC
CureVac
3.5174 of 5 stars
$5.39
+0.2%
$6.83
+26.8%
+96.0%$1.21B$579.18M5.61880
MAZE
Maze Therapeutics
2.4968 of 5 stars
$28.57
+4.2%
$33.83
+18.4%
N/A$1.20B$167.50M0.00121Short Interest ↑
ATAI
atai Life Sciences
3.5621 of 5 stars
$5.40
+5.9%
$11.40
+111.1%
+340.6%$1.19B$310K-7.8380Analyst Forecast
Gap Up
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ARDX
Ardelyx
4.1688 of 5 stars
$5.01
+1.4%
$11.70
+133.5%
-10.9%$1.19B$333.61M-21.7890Upcoming Earnings
SYRE
Spyre Therapeutics
3.0213 of 5 stars
$18.92
-1.1%
$54.29
+186.9%
-35.0%$1.16B$890K-5.5673
PHVS
Pharvaris
2.6758 of 5 stars
$22.07
+0.4%
$32.60
+47.7%
+4.9%$1.15BN/A-6.5730

Related Companies and Tools


This page (NASDAQ:NMRA) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners